GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight
GS030’s Development Will Now Get Higher Priority
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
